Napo Pharmaceuticals
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Napo Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Napo Pharmaceuticals: 3 sponsored US clinical trials, 1 recruiting.
Napo Pharmaceuticals sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Rare Diseases, with 1 trials.
Upper-quartile sponsor footprint
Napo Pharmaceuticals sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
NCT06721871
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
NCT04538625
Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
NCT04192487
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
Where Napo Pharmaceuticals enrollment is open (later-stage tilt)
1 recruiting of 3 indexed (33% open); 2 completed (67%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Rare Diseases (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Napo Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Napo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Napo Pharmaceuticals page
3 registered trials is a research-attention snapshot, not an endorsement of Napo Pharmaceuticals or any single study.
- 1 of Napo Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Rare Diseases is the condition Napo Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Rare Diseases trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Napo Pharmaceuticals pipeline card: 3 registered trials from official public datasets.Report a data error.